Warner-Lambert Sudafed sales up 7% to $43 mil.; Listerine mouthwash gains 6%.
This article was originally published in The Tan Sheet
Executive SummaryWARNER-LAMBERT SUDAFED SALES GAIN 7% IN THIRD QUARTER to $43 mil., the firm reported Oct. 22. The cold medication, one of Warner-Lambert's best performing consumer health care products in the quarter, recently was extended with Cold & Sinus gelcaps and Children's Chewable tablets. Listerine antiseptic mouthwash grew 6% to $98 mil. in the period, and Nix head lice medication increased 60% to $21 mil. Nix benefitted from an increase in the total head lice treatment category and from wider U.S. distribution
You may also be interested in...
Quanta Dialysis is linking up with B. Braun Avitum UK to support patients with Quanta’s personal hemodialysis device in the home. See what Quanta CEO John Milad said about it here.
Cosmetics Europe’s Director-General John Chave discusses next steps in the European Union’s proposed drive to ban manufactured microplastic in all cosmetic products. Industry continues to fight for something more proportionate, but it’s up against powerful forces in today’s European theater.
HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.